Anterior Gradient 2 is a Significant Prognostic Biomarker in Bone Metastasis of Breast Cancer

Jin-Jin Li1, Shuai Wang2, Zhong-Ning Guan1, Jin-Xi Zhang1, Ri-Xin Zhan3 and Jian-Long Zhu1*

1Department of Orthopaedics, Hangzhou Ninth People’s Hospital, Hangzhou, China, 2Department of Pathology, Hangzhou Ninth People’s Hospital, Hangzhou, China, 3Department of Medical Record Management, Hangzhou Ninth People’s Hospital, Hangzhou, China

Background: The study aimed to detect DEGs associated with BRCA bone metastasis, filter prognosis biomarkers, and explore possible pathways.

Methods: GSE175692 dataset was used to detect DEGs between BRCA bone metastatic cases and non-bone metastatic cases, followed by the construction of a PPI network among DEGs. The main module among the PPI network was then determined and pathway analysis on genes within the module was performed. Through performing Cox regression, Kaplan-Meier, nomogram, and ROC curve analyses using GSE175692 and GSE124647 datasets at the same time, the most significant prognostic biomarker was gradually filtered. Finally, important pathways associated with prognostic biomarkers were explored by GSEA analysis.

Results: The 74 DEGs were detected between bone metastasis and non-bone metastasis groups. A total of 15 nodes were included in the main module among the whole PPI network and they mainly correlated with the IL-17 signaling pathway. We then performed Cox analysis on 15 genes using two datasets and only enrolled the genes with $p < 0.05$ in Cox analysis into the further analyses. Kaplan-Meier analyses using two datasets showed that the common biomarker AGR2 expression was related to the survival time of BRCA metastatic cases. Further, the nomogram determined the greatest contribution of AGR2 on the survival probability and the ROC curve revealed its optimal prognostic performance. More importantly, high expression of AGR2 prolonged the survival time of BRCA bone metastatic patients. These results all suggested the importance of AGR2 in metastatic BRCA. Finally, we performed the GSEA analysis and found that AGR2 was negatively related to IL-17 and NF-kB signaling pathways.

Conclusion: AGR2 was finally determined as the most important prognostic biomarker in BRCA bone metastasis, and it may play a vital role in cancer progression by regulating IL-17 and NF-kB signaling pathways.

Keywords: prognosis, bone metastasis, DEGs, BRCA, AGR2

Abbreviations: BRCA, breast cancer; DEGs, differentially expressed genes; PPI, protein-protein interaction; ROC, receiver operating characteristic; GSEA, gene set enrichment analysis; AGR2, Anterior Gradient 2; IL, Interleukin; NF-kB, nuclear factor kappa B.
INTRODUCTION

Breast cancer (BRCA) has become one of the deadliest types of tumors in women worldwide (1). With the progress of diagnosis and treatment technology, primary BRCA no longer poses a serious threat to patients’ lives; instead, metastasis acts as the foremost cause of death (2). At present, distant metastasis has become the primary cause of cancer-related death and occurs in about 20%–30% of BRCA patients (3). It has been noted that BRCA showed a proclivity to metastasize to specific organs, such as the lungs and bones (4). Bone is one of the most common sites of distant breast cancer metastasis (5). Normally, the rigid bone matrix can be able to restrict the growth of tumor cells; however, bone is also a rich reservoir of nutrients and growth factors to support tumor growth through the vicious cycle of osteolytic metastasis (6). Targeting osteoclasts might be a promising approach to stopping bone metastasis. A previous study by Coleman et al. showed that more than 65% of advanced-stage BRCA patients developed bone metastasis (7). The occurrence of bone metastasis exerts a dramatic impact on a patient’s quality of life and causes significant pain, physical disability, and potential loss of employment (8). At present, some therapeutic drugs including bisphosphonates, anti-RANKL antibodies, and Denosumab have been applied as osteoclast targeting agents to inhibit bone metastasis. However, the clinical benefit of these therapeutic agents is unsatisfactory due to their side effects, high cost, or minimal long-term benefit (9). The median overall survival of patients with BRCA metastasis remains unfavorable (10). To further improve disease outcomes, there is an urgent need to explore the biomarkers associated with metastasis in breast cancer.

BRCA metastasis is a complex biological process, in which multiple genes interact and influence each other (11). A range of genes presents the regulation effects on tumor cells, including genes that promote or inhibit metastasis. Screening metastasis-related genes can provide us clues for studying tumor metastasis targets and understanding the potential pathogenic mechanism. Wang et al. constructed a new and convenient prediction model based on 6 genes for predicting the lung metastasis risk of clinical BRCA patients (12). Lu et al. suggested that 5 hub genes were associated with human epidermal growth factor receptor 2 (HER2) positive BRCA with brain metastasis, and the ribosomal pathway seemed to play a very important role (13). Tang et al. determined that 4 crucial genes were associated with the overall survival of BRCA patients, which correlated with BRCA brain metastasis (14). Regarding bone metastasis, Zhang et al. concluded that four genes may play a central role in BRCA bone metastasis (15). Li et al. indicated that CST6 protein and peptides inhibited the BRCA bone metastasis by suppressing CTSB activity and osteoclastogenesis (6). Spadazzi C et al. showed that Trefoil factor-1 (TFF1) upregulation in estrogen-receptor (ER) positive BRCA correlated with an increased risk of bone metastasis (16). Haider et al. suggested that interleukins were the mediators of the tumor cell-bone cell crosstalk during the initiation of BRCA bone metastasis, and interleukins showed potential as therapeutic targets in preventing metastatic outgrowth in bone (17). The expression pattern of these genes associated with metastasis might determine the potential for tumor cell metastasis (18). It was necessary to reveal more differentially expressed genes involved in BRCA bone metastasis.

In the present study, we performed a bioinformatics analysis to explore the BRCA bone metastasis-related biomarkers. The dataset of GSE175692 was obtained to discriminate differentially expressed genes (DEGs) between bone metastatic cases and non-bone metastatic cases. Furthermore, the GSE175692 and GSE124647 datasets were used to filter prognosis-associated genes in BRCA bone metastatic samples. Finally, we performed the gene set enrichment analysis (GSEA) to reveal the significant pathways associated with the prognostic biomarker.

METHODS

Identification of DEGs

In this study, we obtained the gene expression profile of the GSE175692 dataset from the Gene Expression Omnibus (GEO) database. The Robust Multi-array Average (RMA) method was used for pre-processing, including background correcting, normalizing, and calculating expression. The dataset containing 31 BRCA bone metastatic samples and 149 non-bone metastatic samples was used to detect the differentially expressed genes (DEGs) associated with BRCA bone metastasis. Subsequently, the Limma package in R was then used to screen the DEGs. The inclusion criteria for the DEGs were that upregulated genes must have a log2 fold change (logFC) $\geq 2$ and an adjusted p-value $<0.05$, while downregulated genes must have a logFC $<-2$ and an adjusted p-value $<0.05$. The volcano map was used to visualize the DEGs, and a bubble plot was used to present ranked DEGs.

PPI Network Construction and Main Module Analysis

We then used the String database to construct the protein-protein interaction (PPI) network among all DEGs. The organism was Homo sapiens, and the minimum required interaction score was medium confidence. Then Cytoscape was used to visualize the PPI network. Among the whole PPI network, the most significant module containing 15 nodes was identified by MCODE analysis in Cytoscape. The 15 nodes within the module were considered the hub genes. Regarding the 15 genes, we used the R package of clusterProfile to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and the top 5 terms were presented. The GO terms associated with module genes were annotated from aspects of biological process, cellular component, and molecular function. $p < 0.05$ was considered statistically significant.

Filtration of Prognosis-Associated Biomarkers in BRCA Metastasis

Regarding the 15 hub genes within the main module, univariate Cox analysis was performed to initially explore the prognosis-
related biomarkers. The GSE175692 (N = 180) and GSE124647 (N = 140) datasets, all containing patients with BRCA metastasis, were separately used to evaluate the correlation between 15 gene expression levels and overall survival time by univariate Cox regression analysis. The clinicopathologic parameters of the patients with BRCA metastasis in GSE175692 and GSE124647 were presented in Table 1.

Subsequently, the correlation between gene expression value and overall survival was confirmed by performing Kaplan-Meier analysis using GSE175692 and GSE124647 datasets, respectively. Only the genes with \( p < 0.05 \) in Cox analysis were selected for the Kaplan-Meier analysis. Before Kaplan-Meier analysis, all patients were divided into low and high expression groups according to the best cut-off value of gene expression level. In order to determine the best cut-off value, all possible cutoff values between the lower and upper quartiles were computed, and the best performing threshold was used as the cutoff. The

### Table 1: Clinical pathological parameters of patients with breast cancer metastasis in the GEO cohort.

| Characteristics                          | Subgroup       | Number | Percent  |
|-----------------------------------------|----------------|--------|----------|
| **GSE175692**                           |                |        |          |
| Age (years)                              | Percentiles    | (25, 50, 75) | (16, 32, 54) |
| Overall survival time (months)           | Percentiles    | (25, 50, 75) | (49, 57, 70) |
| Overall survival status                  | Alive          | 76     | 42.2%    |
|                                         | Dead           | 104    | 57.8%    |
| Gender                                  | Male           | 1      | 0.6%     |
|                                         | Female         | 179    | 99.4%    |
| Pre-post menopausal                      | Premenopausal  | 68     | 37.8%    |
|                                         | Postmenopausal | 102    | 56.7%    |
|                                         | Unknown        | 10     | 5.5%     |
| Relapsed or de novo metastasis           | Relapsed       | 148    | 82.2%    |
|                                         | De Novo        | 29     | 16.1%    |
| Site of metastatic biopsy                | Distant        | 130    | 72.2%    |
|                                         | Locoregional   | 50     | 27.8%    |
| Metastatic spread                        | Bone           | 31     | 17.2%    |
|                                         | Brain          | 22     | 12.2%    |
|                                         | Breast         | 24     | 13.3%    |
|                                         | Liver          | 30     | 16.7%    |
|                                         | Lung           | 12     | 6.7%     |
|                                         | Lymph Node     | 16     | 8.9%     |
|                                         | Muscle         | 2      | 1.1%     |
|                                         | Ovary          | 4      | 2.2%     |
|                                         | Peritoneum     | 2      | 1.1%     |
|                                         | Pleura         | 10     | 5.6%     |
|                                         | Skin           | 27     | 15.0%    |
| metastatic spread: visceral              | Yes            | 148    | 82.2%    |
|                                         | No             | 31     | 17.2%    |
|                                         | Unknown        | 1      | 0.6%     |
| IHC group                               | Her2+          | 17     | 9.4%     |
|                                         | Hr+/Her2-      | 96     | 54.4%    |
|                                         | Tnbc           | 51     | 28.3%    |
|                                         | Unknown        | 14     | 7.8%     |
| **GSE124647**                           |                |        |          |
| Overall survival time (months)           | Percentiles    | (25, 50, 75) | (12, 24, 41) |
| Overall survival status                  | Alive          | 43     | 30.7%    |
|                                         | Dead           | 97     | 69.3%    |
| Progression-free survival (months)       | Percentiles    | (25, 50, 75) | (2.5, 5.5, 14.3) |
| Progression-free survival status         | Free           | 10     | 7.1%     |
|                                         | Progressed     | 130    | 92.9%    |
| PR status                               | Positive       | 80     | 57.1%    |
|                                         | Negative       | 60     | 42.9%    |
| Visceral disease                        | Yes            | 80     | 57.1%    |
|                                         | No             | 60     | 42.9%    |
| Prior endocrine sensitivity              | Yes            | 70     | 50.0%    |
|                                         | No             | 39     | 27.9%    |
| Stage IV at initial diagnosis            | Yes            | 45     | 32.1%    |
|                                         | No             | 95     | 67.9%    |

Abbreviations: GEO, Gene Expression Omnibus database; PR status, progesterone receptor status; IHC, Immunohistochemistry; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; TNBC, triple-negative breast cancer.
The Clinical Value of AGR2 in Primary Breast Tumor

Further, we evaluated the clinical value of AGR2 in primary breast tumors. The clinical data of BRCA patients and the expression value of AGR2 were obtained from the TCGA database. The patients without AGR2 expression value and survival information were excluded. The clinical pathological parameters of patients were presented in Table 2. Using the TCGA-BRCA dataset, we assessed the expression difference of AGR2 regarding the molecular subtypes and nodal status. In addition, we also performed survival analysis on AGR2 regarding different molecular subtypes using the Kaplan-Meier method and log-rank test. Before survival analysis, all the samples were divided into high and low expression groups according to the best cut-off value of the AGR2 expression level.\( p < 0.05\) was considered statistically significant.

GSEA Analysis on AGR2

The KEGG analysis has indicated the top five pathways associated with hub genes. We further performed the gene set enrichment analysis (GSEA) to reveal the correlation between AGR2 and these five pathways in BRCA metastatic samples. The expression profile for GSEA analysis was from the GSE124647 dataset. In addition, we also explored the correlation between AGR2 and three other important metastasis-related pathways, including nuclear factor kappa B (NF-kB), tumor necrosis factor-beta (TNF-beta), and mammalian target of rapamycin (mTOR) signaling pathways. For GSEA analysis, the criterion for permutations number was 1,000, enrichment statistic was weighted, and the metric for ranking genes was Pearson.

RESULTS

DEGs Identification and Enrichment Analysis

Through GSE175692, we detected 74 DEGs between bone metastasis and non-bone metastasis groups, containing 60 upregulated DEGs and 14 down-regulated DEGs (Figure 1A). The top three upregulated and downregulated DEGs can be found in Figure 1B.

Regarding all the DEGs, a PPI network was constructed. The PPI network contained 65 nodes and 354 edges (Figure 2A). From the whole network, the most significant module with the highest score was determined by MCODE analysis. The core module contained 15 nodes and 104 edges (Figure 2B), and these 15 nodes were regarded as the hub genes. Our result suggested that the module and 15 genes might play an important regulatory role in the whole network.

In terms of 15 hub genes, the vital GO terms were annotated from aspects of biological process, cellular component, and molecular function. The analysis in Figure 3 showed that 15 genes mainly participated in the collagen catabolic process, and were located in the

| Characteristics                      | Subgroup   | Number  | Percent |
|--------------------------------------|------------|---------|---------|
| Age (years)                          | Percentiles| (25, 50, 75) | (49, 59, 66) |
| Overall survival time (days)         | Percentiles| (25, 50, 75) | (441, 822, 1,649) |
| Gender                               | Male       | 12      | 1.1%    |
|                                      | Female     | 1,063   | 98.9%   |
| Cancer stage                         | I          | 181     | 16.8%   |
|                                      | II         | 619     | 57.6%   |
|                                      | III        | 246     | 22.9%   |
|                                      | IV         | 20      | 1.9%    |
|                                      | X          | 9       | 0.8%    |
| ER status                            | Positive   | 795     | 74.0%   |
|                                      | Negative   | 231     | 21.5%   |
|                                      | Unknown    | 49      | 4.6%    |
| PR status                            | Positive   | 686     | 63.6%   |
|                                      | Negative   | 337     | 31.3%   |
|                                      | Unknown    | 52      | 4.8%    |
| HER2 status                          | Positive   | 163     | 15.2%   |
|                                      | Negative   | 551     | 51.3%   |
|                                      | Unknown    | 361     | 33.6%   |

Abbreviations: TCGA, The Cancer Genome Atlas; BRCA, breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

The Detailed Role of AGR2 in BRCA Bone Metastasis and Non-Bone Metastasis

After a series of analyses, our study finally determined that AGR2 was the most vital biomarker among all hub genes. We subsequently used the GSE175692 dataset to detect its differential expression in BRCA bone metastatic cases and non-bone metastatic cases. The Student’s t-test was used to compare the AGR2 expression level between the two groups. The prognostic impact of AGR2 on the overall survival in BRCA bone metastatic cases and non-bone metastatic cases was then explored using Kaplan-Meier analysis, followed by ROC analysis. Before survival analysis, all the samples were divided into high and low expression groups according to the best cut-off value of the AGR2 expression level. The survival difference between high and low expression groups was compared with the log-rank test.\( p < 0.05\) was considered statistically significant.

The Clinical Value of AGR2 in Primary Breast Tumor

Further, we evaluated the clinical value of AGR2 in primary breast tumors. The clinical data of BRCA patients and the expression value of AGR2 were obtained from the TCGA database. The patients without AGR2 expression value and survival information were excluded. The clinical pathological parameters of patients were presented in Table 2. Using the TCGA-BRCA dataset, we assessed the expression difference of AGR2 regarding the molecular subtypes and nodal status. In addition, we also performed survival analysis on AGR2 regarding different molecular subtypes using the Kaplan-Meier method and log-rank test. Before survival analysis, all the samples were divided into high and low expression groups according to the best cut-off value of the AGR2 expression level.\( p < 0.05\) was considered statistically significant.

GSEA Analysis on AGR2

The KEGG analysis has indicated the top five pathways associated with hub genes. We further performed the gene set enrichment analysis (GSEA) to reveal the correlation between AGR2 and these five pathways in BRCA metastatic samples. The expression profile for GSEA analysis was from the GSE124647 dataset. In addition, we also explored the correlation between AGR2 and three other important metastasis-related pathways, including nuclear factor kappa B (NF-kB), tumor necrosis factor-beta (TNF-beta), and mammalian target of rapamycin (mTOR) signaling pathways. For GSEA analysis, the criterion for permutations number was 1,000, enrichment statistic was weighted, and the metric for ranking genes was Pearson.

RESULTS

DEGs Identification and Enrichment Analysis

Through GSE175692, we detected 74 DEGs between bone metastasis and non-bone metastasis groups, containing 60 upregulated DEGs and 14 down-regulated DEGs (Figure 1A). The top three upregulated and downregulated DEGs can be found in Figure 1B.

Regarding all the DEGs, a PPI network was constructed. The PPI network contained 65 nodes and 354 edges (Figure 2A). From the whole network, the most significant module with the highest score was determined by MCODE analysis. The core module contained 15 nodes and 104 edges (Figure 2B), and these 15 nodes were regarded as the hub genes. Our result suggested that the module and 15 genes might play an important regulatory role in the whole network.

In terms of 15 hub genes, the vital GO terms were annotated from aspects of biological process, cellular component, and molecular function. The analysis in Figure 3 showed that 15 genes mainly participated in the collagen catabolic process, and were located in the
extracellular matrix. For molecular function, 15 hub genes were mainly involved in growth factor activity and receptor activity.

The study also explored the possible pathways associated with 15 hub genes via KEGG analysis. We found that 15 hub genes significantly correlated with the cancer pathway, IL-17 signaling pathway, TNF signaling pathway, breast cancer, and estrogen signaling pathway (Figure 4A). It followed that these pathways were associated with the endocrine system, immune system, and signal transduction (Figure 4B).

**Significant Hub Genes Identification Associated With Patient's Prognosis**

Subsequently, the GSE175692 and GSE124647 datasets were separately used to detect the most significant prognosis-associated
hub genes among 15 genes. The univariate Cox regression analysis was initially performed to filter the hub genes, and only the genes with $p < 0.05$ in Cox analysis were enrolled into the further Kaplan-Meier analysis, nomogram, and ROC analysis. Combining the Cox, Kaplan-Meier, nomogram, and ROC analyses, the most important prognosis-related genes can be gradually determined.

Cox regression analysis using the GSE175692 dataset (Figure 5) initially indicated that 11 hub genes presented significant prognostic impact (all $p < 0.05$). The Kaplan-Meier analysis further confirmed the correlation between the expression value of these 11 genes and the overall survival time of patients with BRCA metastasis (Figure 6). Taken together, our results indicated that high expressions of AGR2, TFF3, ESR1, TFF1, and FOXA1 were related to longer overall survival time of patients (all $p < 0.05$). However, high expressions of PROM1, CXCL10, MMP3, WNT2, CCL2, TFF1, and FOX1 were related to shorter overall survival time of patients (all $p < 0.05$).
and MMP7 were related to the poor prognosis of patients (all \( p < 0.05 \)).

The Cox regression analysis using the GSE124647 dataset showed that only 4 genes were related to the patient’s prognosis (Figure 5). Kaplan-Meier survival analysis then indicated that only AGR2 expression level was associated with the overall survival of patients. Compared with the low expression group, the AGR2 high expression group showed a longer survival time (Figure 7, \( p = 0.0044 \)).

We further evaluated the prognosis prediction performance of significant prognosis-related genes \((p < 0.05 \text{ in Cox analysis})\) in metastatic BRCA by ROC analysis. The ROC curve indicated that AGR2 presented the best prediction performance for the survival probability of BRCA metastatic samples in the GSE124647 dataset (Figure 8A). In the GSE175692 dataset, the prognostic performance of AGR2 was next only to ESR1 and TFF1 (Figure 8B). These results suggested the favorable performance of AGR2 for predicting prognosis in BRCA metastasis.

Also, we conducted a nomogram to assess the contribution of these hub genes \((p < 0.05 \text{ in Cox analysis})\) on the survival probability of patients with BRCA metastasis using 2 datasets. Among 11 prognosis-related genes in GSE175692, AGR2 made the largest contribution to the survival probability of patients, contributing 100 scores (Figure 8C). Among 4 prognosis-related genes in GSE124647, AGR2 also presented the highest
FIGURE 7 | The prognostic impact of 4 hub genes in patients with BRCA metastasis using the GSE124647 dataset. The genes with \( p < 0.05 \) in Cox analysis were selected for Kaplan-Meier analysis. The comparison result was presented with \( p \) value and HR (95% CI). Abbreviation: HR, hazard ratio; CI, confidence interval; BRCA, breast cancer.

FIGURE 8 | Prognostic performance analysis on prognosis-related hub genes in 2 datasets. (A) ROC analysis on 4 hub genes in the GSE124647 dataset. (B) ROC analysis on 11 hub genes in the GSE175692 dataset. (C) Nomogram analysis. Points are the scores corresponding to a single gene. Total points are the sum of the Points that all genes. The length of the line corresponding to each gene in the prognostic nomogram reflects the contribution of each gene to one patient’s outcome. The hub genes with \( p < 0.05 \) in Cox regression analysis were enrolled into the nomogram and ROC analysis. Abbreviation: ROC, receiver operating characteristic. AUC, area under the curve.
contribution score for overall survival probability of patients as AGR2 contributed 100 points. It followed that AGR2 showed the optimal prognostic performance on the survival probability of BRCA metastatic patients.

Under the combination of Cox regression analysis, Kaplan-Meier analysis, nomogram, and ROC analysis using GSE175692 and GSE124647 datasets, AGR2 was finally identified as the most significant prognosis-related biomarker in BRCA metastasis.

The Clinical Value of AGR2 in BRCA Bone Metastasis and Primary Breast Tumor

As AGR2 was finally identified as the most significant prognostic biomarker in metastatic BRCA samples, we further explored the detailed role of AGR2 in BRCA bone metastasis using the GSE175692 dataset. Differential expression analysis showed that AGR2 was highly expressed in BRCA bone metastatic cases compared with that in the non-bone metastatic cases (Figure 9A, \( p = 0.0063 \)). AGR2 high expression was conducive to the overall survival of BRCA bone metastatic samples (Figure 9B, \( p = 0.04 \)), and ROC analysis showed that AGR2 presented a favorable performance for predicting a patient’s prognosis (Figure 9C). Also, AGR2 showed significant prognostic value (Figure 9D) and good prediction performance (Figure 9E) in BRCA non-bone metastatic patients.

Due to the significance of molecular subtypes of BRCA, we also explored the expression pattern and prognostic impact of AGR2 in primary breast tumors. The results indicated that AGR2 expression was related to the subtypes and nodal status of the primary tumor (Figure 10A). Kaplan-Meier analysis showed that expression of AGR2 was not related to the prognosis of patients under different subtypes (Figure 10B).

AGR2 Associated Mechanism Exploration in Metastatic BRCA

Due to the importance of AGR2 in BRCA metastatic samples, AGR2-associated pathways were also explored through GSEA analysis. According to our KEGG analysis, 15 hub genes were involved in the cancer pathway, IL-17 signaling pathway, TNF signaling pathway, breast cancer, and estrogen signaling pathway. Hence, we further explored the relationship between AGR2 and these five pathways in metastatic BRCA samples (Figure 11). Our results showed that AGR2 was negatively related to these five pathways, but only the IL-17 signaling pathway showed statistical significance (NES = −1.4814, \( p = 0.035 \)). In addition, we also explored the correlation between AGR2 and three significant metastasis pathways. The result showed that AGR2 negatively correlated with the NF-kB signaling pathway (NES = −2.0377, \( p < 0.001 \)), but did not relate to mTOR and TGF-\( \beta \) pathways. Briefly,
FIGURE 10 | The expression and survival analysis on AGR2 regarding the subtype of the primary breast tumor. (A) The expression of AGR2 based on the subtypes of BRCA and nodal status. (B) The correlation between AGR2 expression and overall survival time of patients with different subtypes of BRCA. The comparison result was presented with p value and HR (95% CI). Abbreviation: HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval; OS, overall survival; BRCA, breast cancer.

FIGURE 11 | The GSEA analysis on AGR2 in BRCA metastatic samples in GSE124647. Abbreviation: BRCA, breast cancer; GSEA, gene set enrichment analysis; NES, normalized enrichment score; AGR2, Anterior Gradient 2; IL-17, interleukin-17; TNF, tumor necrosis factor; NF-κB, nuclear factor kappa-β; mTOR, mammalian target of rapamycin; TGF-β, transforming growth factor β.
AGR2 might significantly correlate with IL-17 and NF-κβ signaling pathways in metastatic BRCA.

DISCUSSION

In this study, we detected 74 BRCA bone metastasis-related DEGs by bioinformatics analysis. Among the whole PPI network on DEGs, we determined the most significant module which contained 15 hub genes. Then, five significant KEGG pathways associated with 15 genes were detected. Especially, 15 hub genes were mainly related to the IL-17 signaling pathway, referring to the immune system. IL-17 family has been proved to play an important role in the specific organ metastasis of BRCA. Several studies have shown that IL-17A can lead to metastasis to the lungs and bones (19, 20). IL-17E was proposed to be related to lung metastasis formation in BRCA (21). Detailed IL-17 signaling in this study needs further confirmation. Our study also found the involvement of TNF and estrogen signaling pathways. The study has found that CD137, a member of the TNF receptor superfamily, can promote bone metastasis of BRCA by enhancing the migration and osteoclast differentiation of monocytes/macrophages (22). Cletus et al. found that compared to ER-positive BRCA, ER-negative BRCA was more likely to metastasize to the bone but less likely to the brain, liver, and lung, and less likely to result in multiple metastases (23). These pathways are all significantly correlated with metastatic patterns of BRCA.

Furthermore, we gradually conducted univariate Cox analysis, Kaplan-Meier, nomogram, and ROC analyses on 15 genes using two datasets at the same time to identify the most significant prognosis-related gene. It should be noted that a similar study by Yu et al. recently published also revealed the bone metastasis-related DEGs using the same datasets (24), but the overall arrangement of the two reports was different. The Yu et al. study firstly identified the DEGs and evaluated the clinical value of hub genes. Subsequently, they verified vital genes using the other dataset. Our work aimed to filter important hub genes using two datasets at the same time, and finally determined the hub genes according to the comprehensive result of the two datasets. Under the series of filtration, AGR2 was finally determined as the most significant prognosis-related biomarker in metastatic BRCA in this study. AGR2 is a developmentally regulated gene belonging to the protein disulfide isomerase (PDI) gene family (25). A previous study enrolled 107 primary breast tumors of patients who had developed distant metastasis and classified all patients into two groups according to the site of relapse (bone vs. non-bone), finding that AGR2 was highly expressed in the samples with relapse to bone (26). Guo et al. found that AGR2 expression was significantly associated with histologic subtype, histological grade, estrogen status, progesterone status, and its prognostic impact was related to histological grade (27). In this study, we confirmed that the expression and prognostic value of AGR2 were correlated with the subtypes of primary breast tumors. In addition, AGR2 has been identified as a clinically relevant factor that modulated the behavior and response of hormone-dependent cancers such as BRCA and prostate cancer (28). In BRCA, AGR2 expression was related to ER-positive tumors, and AGR2 was directly targeted by ER-alpha, which was preferentially bound in tumors with poor outcomes (29). Lacambra et al. also indicated that the prognostic impact of AGR2 expression could be related to treatment outcome in ER-positive BRCA (30). It followed that the prognostic impact of AGR2 was significantly related to ER status involved in BRCA.

In addition, we found a correlation between AGR2 higher expression and longer overall survival time in BRCA bone metastatic samples. We further explored the potential mechanism associated with AGR2 in metastatic BRCA. Through analyzing the correlation between AGR2 and five KEGG pathways, we found that AGR2 only significantly correlated with the IL-17 signaling pathway with a negative correlation. We speculated that AGR2 high expression was conducive to the prognosis of patients, which might be due to the negative regulation of the IL-17 pathway. The result further confirmed the importance of the IL-17 signaling pathway in metastatic BRCA. At present, regulation of the IL-17 pathway associated with AGR2 in BRCA was not reported. In addition, we also confirmed the relation between AGR2 and three important metastatic pathways. We found that AGR2 was negatively related to the NF-κβ signaling pathway involved in metastatic BRCA. Aberrant activation of the NF-κβ signaling cascade was connected to carcinogenesis (31). The NF-κβ pathway was significantly related to the bone metastasis in BRCA (32). The AGR2 showed a negative correlation with this pathway in our study, suggesting that AGR2 high expression may inhibit the carcinogenesis of this pathway and thus improve the patient’s prognosis.

This study identified an important bone metastasis-related biomarker which correlated with the patient’s prognosis. However, several limitations of this study needed to be acknowledged. The sample size for prognosis analysis in BRCA bone metastasis was insufficient, hence, a larger sample size is needed to enhance the credibility of these results in future works. In addition, pathways associated with AGR2 including IL-17 and NF-κβ signaling pathways were initially identified in this study, and the detailed regulation in BRCA bone metastasis should be verified by functional analysis.

CONCLUSION

This study identified 74 DEGs associated with BRCA bone metastasis. A main module in the PPI network among DEGs was determined, which included 15 DEGs. KEGG analysis showed that 15 genes were mainly involved in the IL-17 signaling pathway referring to the immune system. Further, we gradually performed the univariate Cox analysis, Kaplan-Meier, nomogram, and ROC analyses on 15 genes. AGR2 was finally proved to present the most important role, as it showed the largest contribution and optimal
prognostic performance on survival probability of metastatic BRCA patients, as well as significant prognostic impact in single bone metastatic BRCA. Pathway analysis found that AGR2 negatively correlated with NF-kB and IL-17 signaling pathways. The present study provides a useful prognostic biomarker in BRCA bone metastasis, and detailed function in cancer progression needs more functional verification.

**DATA AVAILABILITY STATEMENT**

The datasets used and/or analyzed during the current study are available in the following links: https://www.jianguoyun.com/p/DXnjM64Qy_3mChj_-80EIAA.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2018) 68(6):394–424. doi:10.3322/caac.21492

2. Weigelt B, Peterse JL, van ’t Veer LJ. Breast Cancer Metastasis: Markers and Models. *Nat Rev Cancer* (2005) 5(8):591–602. doi:10.1038/nrc1670

3. Brockton NT, Gill SJ, Laborge SL, Paterson AH, Cook LS, Vogel HJ, et al. The Breast Cancer to Bone (B2B) Metastases Research Program: a Multi-Disciplinary Investigation of Bone Metastases from Breast Cancer. *BMC cancer* (2015) 15:512. doi:10.1186/s12885-015-1528-y

4. Fidler IJ. The Pathogenesis of Cancer Metastasis: the ‘seed and soil’ Hypothesis Revisited. *Nat Rev Cancer* (2003) 3(6):453–8. doi:10.1038/nrc1098

5. Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, et al. Systematic Review and Meta-Analysis on the Proportion of Patients with Breast Cancer Who Develop Bone Metastases. *Crit Rev Oncol Hematol* (2017) 115:67–80. doi:10.1016/j.critrevonc.2017.04.008

6. Li X, Liang Y, Lian C, Peng F, Xiao Y, He Y, et al. CST6 Protein and Peptides Inhibit Breast Cancer Bone Metastasis by Suppressing CTSA Activity and Osteoclastogenesis. *Theranostics* (2021) 11(20):9821–32. doi:10.7150/thno.62187

7. Coleman RE. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. *Clin Cancer Res* (2006) 12(20):6243s–9s. doi:10.1158/1078-0432.CCR-06-0931

8. Hanksins ML, Smith CN, Hersh B, Heim T, Belayneh R, Dooley S, et al. Prognostic Factors and Survival of Patients Undergoing Surgical Intervention for Breast Cancer Bone Metastases. *J Bone Oncol* (2021) 29:100363. doi:10.1016/j.jbo.2021.100363

9. Domschke C, Schuetz F. Side Effects of Bone-Targeted Therapies in Advanced Breast Cancer. *Breast care (Basel, Switzerland)* (2014) 9(5):332–6. doi:10.1159/000368844

10. Stieg PS. Targeting Metastasis. *Nat Rev Cancer* (2016) 16(4):201–18. doi:10.1038/nrc.2016.23

11. Kozlowski J, Kozlowska A, Kocki J. Breast Cancer Metastasis - Insight into Selected Molecular Mechanisms of the Phenomenon. *Postepy Hig Med Dosw* (2015) 69:447–51. doi:10.5604/17322693.1148710

12. Wang L, Wang W, Zeng S, Zheng H, Lu Q. Construction and Validation of a 6-gene Nomogram Discriminating Lung Metastasis Risk of Breast Cancer Patients. *PloS one* (2020) 15(12):e0244693. doi:10.1371/journal.pone.0244693

13. Lu X, Gao C, Liu C, Zhuang J, Su P, LI H, et al. Identification of the Key Pathways and Genes Involved in HER2-Positive Breast Cancer with Brain Metastasis. *Pathol Res Pract* (2019) 215(8):152475. doi:10.1016/j.prrp.2019.152475

14. Tang D, Zhao X, Zhang L, Wang Z, Wang C. Identification of Hub Genes to Regulate Breast Cancer Metastasis to Brain by Bioinformatics Analyses. *J Cell Biochem* (2019) 120(6):9522–31. doi:10.1002/jcb.28228

**AUTHOR CONTRIBUTIONS**

J-LZ made contributions to conception and design, SW and Z-NG acquired the data, and analyzed the consequence. J-XZ and R-XZ designed the study, contributed to the discussion, and revised the manuscript. J-LZ confirmed the authenticity of all the raw data. All authors have read and approved the final manuscript.

**CONFLICT OF INTEREST**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

15. Zhang Y, Huang X, Liu J, Chen G, Liu C, Zhang S, et al. New Insight into Long Non-coding RNAs Associated with Bone Metastasis of Breast Cancer Based on an Integrated Analysis. *Cancer Cell Int* (2021) 21(1):372. doi:10.1186/s1295-021-02568-7

16. Spadacci C, Mercatali L, Esposito M, Wei Y, Liverani C, De Vita A, et al. Trefoil Factor-1 Upregulation in Estrogen-Receptor Positive Breast Cancer Correlates with an Increased Risk of Bone Metastasis. *Bone* (2021) 144:115775. doi:10.1016/j.bone.2020.115775

17. Haider M, Riddelmaier N, Smit D, Taipaleenniemi H. Interleukins as Mediators of the Tumor Cell-Bone Cell Crosstalk during the Initiation of Breast Cancer Bone Metastasis. *Int J Mol Sci* (2021) 22(6):2898. doi:10.3390/ijms22062898

18. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer. *Nature* (2002) 415(6871):530–6. doi:10.1038/415530a

19. Roy LD, Ghosh S, Pathangey LR, Tindel TL, Gruber HE, Mukherjee P. Collagen Induced Arthritis Increases Secondary Metastasis in MMTV-PyMT Mouse Model of Mammary Cancer. *BMC cancer* (2011) 11:365. doi:10.1186/1471-2407-11-365

20. Roy LD, Sahraei M, Scchettini JL, Gruber HE, Besnmer DM, Mukherjee P. Systemic Neutralization of IL-17A Significantly Reduces Breast Cancer Associated Metastasis in Arthritic Mice by Reducing CXCL12/SDF-1 Expression in the Metastatic Niches. *BMC cancer* (2014) 14:22. doi:10.1186/1471-2407-14-225

21. Fabre JAS, Giustiniani N, Garbar C, Merrouche Y, Antonielli F, Bensusan A. Interleukin-17 Family of Cytokines in Breast Cancer. *Int J Mol Sci* (2018) 19(12):E3880. doi:10.3390/ijms19123880

22. Jiang P, Gao W, Ma T, Wang R, Piao Y, Dong X, et al. CD137 Promotes Bone Metastasis of Breast Cancer by Enhancing the Migration and Osteoclast Differentiation of Monocytes/macrophages. *Theranostics* (2019) 9(10):2950–66. doi:10.7150/thno.29617

23. Arciero CA, Guo Y, Jiang R, Behera M, O’Regan R, Peng L, et al. ER(+) /HER2(+) Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER(-)/HER2(+) Breast Cancer. *Clin Breast Cancer* (2019) 19(4):236–45. doi:10.1016/j.clbc.2019.02.001

24. Yu C-c, Wu Y-n, Hu K-m, Zhang S-z. Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis. *BioMed Res Int* (2022) 2022:4123622. doi:10.1155/2022/4123622

25. Gray TA, MacLaine NJ, Michio CO, Bouchalova P, Murray E, Howie J, et al. Anterior Gradient-3: a Novel Biomarker for Ovarian Cancer that Mediates Cisplatin Resistance in Xenograft Models. *J Immunol Methods* (2012) 378(1-2):230–32. doi:10.1016/j.jimc.2012.01.013

26. Smid M, Wang Y, Klijn J, Siewerts A, Zhang Y, Atkins D, et al. Genes Associated with Breast Cancer Metastatic to Bone. *J Clin Oncol* (2006) 24(15):2261–7. doi:10.1200/JCO.2005.03.8802

27. Guo J, Gong G, Zhang B. Identification and Prognostic Value of Anterior Gradient Protein 2 Expression in Breast Cancer Based on Tissue Microarray. *Tumour Biol* (2017) 39(7):1010428317713392. doi:10.1177/1010428317713392
28. Brychtová V, Vojtěsek B, Hrstka R. Anterior Gradient 2: a Novel Player in Tumor Cell Biology. Cancer Lett. (2011) 304(1):1–7. doi:10.1016/j.canlet.2010.12.023
29. Salmans ML, Zhao F, Andersen B. The Estrogen-Regulated Anterior Gradient 2 (AGR2) Protein in Breast Cancer: a Potential Drug Target and Biomarker. Breast Cancer Res. (2013) 15(2):204. doi:10.1186/bcr3408
30. Lacambra MD, Tsang JY, Ni YB, Chan SK, Tan PH, Tse GM. Anterior Gradient 2 Is a Poor Outcome Indicator in Luminal Breast Cancer. Ann Surg Oncol. (2015) 22(11):3489–96. doi:10.1245/s10434-015-4420-8
31. Yenmis G, Yaprak Sarac E, Besli N, Soydas T, Tastan C, Dilek Kancagi D, et al. Anti-cancer Effect of Metformin on the Metastasis and Invasion of Primary Breast Cancer Cells through Mediating NF-kB Activity. Acta Histochem. (2021) 123(4):151709. doi:10.1016/j.acthis.2021.151709
32. Zhang Z, Yao Y, Yuan Q, Lu C, Zhang X, Yuan J, et al. Gold Clusters Prevent Breast Cancer Bone Metastasis by Suppressing Tumor-Induced Osteoclastogenesis. Theranostics. (2020) 10(9):4042–55. doi:10.7150/thno.42218

Copyright © 2022 Li, Wang, Guan, Zhan and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.